GS24-B047 (Changchun GeneScience Pharma)

GS24-B047 (Changchun GeneScience Pharma): sourced facts only. name: "GS24-B047 bound to DLL3 with sub-nanomolar affinity, recognizing a distinct, more membrane-proximal epitope as compared to Tarlatamab, and effectively mediated simultaneous engagement of DLL3 on tumor cells and CD3 on T cells." [DOI:10.1158/1538-7445.am2026-7778]; target: "GS24-B047 bound to DLL3 with sub-nanomolar affinity, recognizing a distinct, more membrane-proximal epitope as compared to Tarlatamab, and effectively mediated simultaneous engagement of DLL3 on tumor cells and CD3 on T cells." [DOI:10.1158/1538-7445.am2026-7778]; developer: "1Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China;" [DOI:10.1158/1538-7445.am2026-7778]; stage: "In vivo, GS24-B047 treatment resulted in significant and durable tumor regression in multiple CDX models of SCLC, showing enhanced anti-tumor activity when compared to clinical benchmarks." [DOI:10.1158/1538-7445.am2026-7778]